New study shows that a Universal Medication Schedule could help diabetes patients.
“Basically, everything we know will be gutted over the next three years.”
Pharmacists on P&T committees are going to face issues that range from biosimilar naming systems to challenges in dispensing and costs.
According to PBMs, those drug coupons are something else.
PBMs have dodged state-mandated requirements for transparency in generics drug pricing, so many states are rewriting their laws.
Five years of imatinib treatment for CML = >$100,000 saved per patient.
Value-based care is transforming the world of healthcare. Simple cost management must give way to utilization management, and alignment of stakeholder services is inevitable.
Key trends point to a collaboration between pharmacies and healthcare stakeholders that will shape better delivery of patient education, adherence support, and financial assistance.
Cost of treatment often forces aging patients on limited incomes to choose between paying for medications or for food and rent.
Validation through inclusion in Medicare Part B could lead to recognition of pharmacists as healthcare providers across the board.